What is the recommended treatment approach for insomnia in adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Insomnia Treatment

Cognitive-behavioral therapy for insomnia (CBT-I) is the first-line treatment for chronic insomnia in adults and should be initiated before considering pharmacological interventions. 1, 2

Treatment Algorithm

Step 1: Initial Treatment - CBT-I

  • Start with multicomponent CBT-I as the primary intervention, delivered either in-person or digitally 1, 2
  • CBT-I has demonstrated superior long-term durability compared to medications, with sustained benefits after treatment discontinuation 3
  • This recommendation applies to all adults regardless of age and includes patients with medical or psychiatric comorbidities 2

Key advantage: CBT-I provides durable effects that persist after treatment ends, unlike pharmacological options which lose efficacy upon discontinuation 3

Step 2: When CBT-I is Insufficient or Unavailable

If CBT-I proves ineffective after an adequate trial or is not accessible, pharmacological treatment can be offered 2. The 2017 AASM guideline emphasized that medications should be considered primarily in three scenarios:

  • Patients unable to participate in CBT-I
  • Residual symptoms following adequate CBT-I trial
  • Temporary adjunct to CBT-I in select cases 1

Step 3: Pharmacological Options

For short-term use (≤4 weeks):

  • Sleep onset insomnia: Triazolam, ramelteon, or zaleplon 1
  • Sleep maintenance insomnia: Low-dose doxepin or suvorexant 1, 4
  • Combined onset and maintenance: Temazepam, zolpidem, or eszopiclone 1
  • Benzodiazepines and benzodiazepine receptor agonists are appropriate for this duration 2

For longer-term use (up to 3 months or more):

  • Orexin receptor antagonists (including newer agents like daridorexant and lemborexant) can be used for 3 months or longer in selected cases 2, 1
  • Prolonged-release melatonin for patients ≥55 years (up to 3 months) 2
  • Longer-term benzodiazepines/BZRAs may be appropriate in some cases after careful individual risk-benefit assessment 2

Step 4: Combination Treatment Considerations

The 2026 AASM combination treatment guideline addresses a critical gap: while combining CBT-I with medication may decrease latency to treatment response, it might diminish the durability of CBT-I's positive effects 3. Use combination therapy judiciously and primarily as a temporary bridge rather than long-term strategy.

What NOT to Use

Conditional recommendations AGAINST the following due to insufficient efficacy evidence, absence of high-quality data, or safety concerns 1, 2:

  • Trazodone
  • Tiagabine
  • Diphenhydramine and other antihistamines
  • Melatonin (fast-release formulations)
  • Tryptophan
  • Valerian
  • Antipsychotics
  • Ramelteon (per European guidelines)
  • Sleep hygiene as a single-component therapy 1

Critical Clinical Pitfalls

Common mistake: Using sleep hygiene education alone as treatment. While necessary, sleep hygiene measures are insufficient when used in isolation and received a conditional recommendation against single-component use 1, 5

Important caveat: Although guidelines are based on daily medication use as evaluated in randomized trials, clinical practice may involve non-nightly use for patients who don't require nightly treatment 6

Diagnosis reminder: Clinical diagnosis based on careful history using ICSD or DSM criteria is sufficient; objective sleep testing is only needed when suspecting comorbid sleep disorders like sleep apnea 1

Rationale for CBT-I Priority

The strong preference for CBT-I over pharmacotherapy is evidence-based:

  • Patients prefer behavioral-psychological treatments due to perceived better long-term efficacy
  • Provides more benefits for daytime symptoms
  • Has fewer side effects compared to medications 1
  • Shows durable effects that persist after treatment discontinuation, unlike medications 3

The treatment hierarchy is clear: CBT-I first, medications second, and combination therapy reserved for specific clinical scenarios where monotherapy proves inadequate.

References

Guideline

combination treatment for chronic insomnia disorder in adults: an american academy of sleep medicine clinical practice guideline.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2026

Research

Insomnia.

Lancet (London, England), 2022

Research

Insomnia disorder.

Minerva medica, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.